GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Recce Pharmaceuticals Ltd (ASX:RCE) » Definitions » Equity-to-Asset

Recce Pharmaceuticals (ASX:RCE) Equity-to-Asset : 0.10 (As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is Recce Pharmaceuticals Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Recce Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Dec. 2023 was A$0.53 Mil. Recce Pharmaceuticals's Total Assets for the quarter that ended in Dec. 2023 was A$5.47 Mil.

The historical rank and industry rank for Recce Pharmaceuticals's Equity-to-Asset or its related term are showing as below:

ASX:RCE' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.01   Med: 0.66   Max: 0.95
Current: 0.1

During the past 8 years, the highest Equity to Asset Ratio of Recce Pharmaceuticals was 0.95. The lowest was -1.01. And the median was 0.66.

ASX:RCE's Equity-to-Asset is ranked worse than
82.21% of 1563 companies
in the Biotechnology industry
Industry Median: 0.66 vs ASX:RCE: 0.10

Recce Pharmaceuticals Equity-to-Asset Historical Data

The historical data trend for Recce Pharmaceuticals's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Recce Pharmaceuticals Equity-to-Asset Chart

Recce Pharmaceuticals Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Equity-to-Asset
Get a 7-Day Free Trial -0.44 0.71 0.95 0.80 -1.01

Recce Pharmaceuticals Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.93 0.80 0.47 -1.01 0.10

Competitive Comparison of Recce Pharmaceuticals's Equity-to-Asset

For the Biotechnology subindustry, Recce Pharmaceuticals's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Recce Pharmaceuticals's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Recce Pharmaceuticals's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Recce Pharmaceuticals's Equity-to-Asset falls into.



Recce Pharmaceuticals Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Recce Pharmaceuticals's Equity to Asset Ratio for the fiscal year that ended in Jun. 2023 is calculated as

Equity to Asset (A: Jun. 2023 )=Total Stockholders Equity/Total Assets
=-2.589/2.556
=

Recce Pharmaceuticals's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )=Total Stockholders Equity/Total Assets
=0.534/5.473
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Recce Pharmaceuticals  (ASX:RCE) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Recce Pharmaceuticals Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Recce Pharmaceuticals's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Recce Pharmaceuticals (ASX:RCE) Business Description

Traded in Other Exchanges
Address
180 George Street, Level 23, Salesforce Tower, Sydney, NSW, AUS, 2000
Recce Pharmaceuticals Ltd is an Australia-based globally-focused biotechnology company engaged in the development and commercialization of a new class of antibiotics. It operates in only one business segment being research and development of pharmaceutical drugs. The firm operates in three geographic segments being Australia, the United Kingdom, and the United States of America, of which the majority of the revenue comes from Australia. The company offers antibiotic drugs to treat the diseases caused by various bacterias namely Sepsis, Helicobacter Pylori, Escherichia coli, Pseudomonas aeruginosa, and others.

Recce Pharmaceuticals (ASX:RCE) Headlines

No Headlines